Responses

Download PDFPDF
Extended report
Lupus Atherosclerosis Prevention Study (LAPS)
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Corrected version of the e-letter "Selection bias may have blunted the effect of atorvastatin on the progression of atherosclerosis in systemic lupus erythematosus patients: Commentary on the Lupus Prevention Atherosclerosis Study (LAPS) "

    Dear editor,

    We read with interest the study by Petri et al. (1), which showed absence of effect of atorvastatin on the change in coronary artery calcium and carotideal intima media thickness in lupus patients treated for 2 years. Lupus was been considered a coronary heart disease (CHD) equivalent by some authors given the major increase of cardiovascular risk in this disease (2).

    The authors reported that patie...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    About Lupus Atherosclerosis Prevention Study (LAPS)
    • JM Sabio, MD, PhD
    • Other Contributors:
      • N.Navarrete-Navarrete

    Dear Editor,

    We read with great interest the article of Petri et al [1] addressing the effect of atorvastatin 40 mg daily on subclinical atherosclerosis (ATS), systemic inflammation and disease activity in patients with systemic lupus erythematosus (SLE). Contrary to expectations, atorvastain had no effect on any of these parameters after 2 years of follup-up. Although these findings are clinically relevant, some issues...

    Show More
    Conflict of Interest:
    None declared.